Sepideh Gholami, Liver and Pancreas Surgeon-Scientist at Northwell Health and Cold Spring Harbor Laboratory, shared a post on LinkedIn:
“Excited to share our recent work on CXCR4 in metastatic colorectal cancer.
Across >15,000 samples, higher CXCR4 expression was linked to distinct immune features (CXCR4 mRNA expression was positively associated with high TMB, dMMR, and positive PD-L1 status), worse outcomes in primary tumors, but improved survival in metastatic disease, especially with immunotherapy.
A reminder that biomarkers are context-dependent, and the liver/metastatic setting changes the story.
Grateful to the team and the Caris Foundation for this collaborative effort.”
Title: CXCR4 mRNA overexpression: an indicator of poor survival and predictor of response to immune checkpoint inhibitors in patients with metastatic colorectal cancer
Authors: Sepideh Gholami, Anwaar Saeed, Yasmine Baca, Andrew Hinton, Lyudmyla Demyan, Mustafa Abidalhassan, Joanne Xiu, Gulam A. Manji, Andreas Seeber, Benjamin A. Weinberg, Moh’d Khushman, Anthony F. Shields, Heinz-Josef Lenz, John Marshall, Emil Lou
Other articles featuring Sepideh Gholami on OncoDaily.